7-hydroxymethotrexate and Breast-Neoplasms

7-hydroxymethotrexate has been researched along with Breast-Neoplasms* in 3 studies

Reviews

1 review(s) available for 7-hydroxymethotrexate and Breast-Neoplasms

Article	Year
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis. The Journal of rheumatology. Supplement, 1985, Volume: 12 Suppl 12 The clinical pharmacokinetics of methotrexate, particularly when the drug is used at low doses for nonmalignant disease, are complicated and require extensive study. Bioavailability of the drug may be influenced--at least in part--by food intake. Biliary excretion can compensate for decreased renal excretion of methotrexate to some degree. However, further studies of the renal excretion of methotrexate are needed. Topics: Animals; Arthritis, Rheumatoid; Bile; Biological Availability; Brain; Breast Neoplasms; Cell Line; Half-Life; Humans; Intestinal Absorption; Kidney; Kinetics; Liver; Metabolic Clearance Rate; Methotrexate; Neoplasms; Psoriasis; Tritium	1985

Article

Year

Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis.

The Journal of rheumatology. Supplement, 1985, Volume: 12 Suppl 12

The clinical pharmacokinetics of methotrexate, particularly when the drug is used at low doses for nonmalignant disease, are complicated and require extensive study. Bioavailability of the drug may be influenced--at least in part--by food intake. Biliary excretion can compensate for decreased renal excretion of methotrexate to some degree. However, further studies of the renal excretion of methotrexate are needed.

Topics: Animals; Arthritis, Rheumatoid; Bile; Biological Availability; Brain; Breast Neoplasms; Cell Line; Half-Life; Humans; Intestinal Absorption; Kidney; Kinetics; Liver; Metabolic Clearance Rate; Methotrexate; Neoplasms; Psoriasis; Tritium

1985

Other Studies

2 other study(ies) available for 7-hydroxymethotrexate and Breast-Neoplasms

Article	Year
Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochemical pharmacology, 1987, Jul-15, Volume: 36, Issue:14 Topics: Breast Neoplasms; Cell Line; Folic Acid; Folic Acid Antagonists; Humans; Intracellular Fluid; Methotrexate; Neoplasm Proteins; Polyglutamic Acid; Tetrahydrofolate Dehydrogenase	1987
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. Cancer drug delivery, 1987, Volume: 4, Issue:3 Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively. The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate. The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively. Urinary clearance of methotrexate was 3.46 +/- 1.4 1/h. In contrast, urinary excretion of 7-hydroxy-methotrexate was not linear. These results confirm the protein binding of metabolite to serum albumin and may suggest that distribution of 7-hydroxy-methotrexate is different from unchanged drug or that the metabolite can be eliminated by another route, such as bile. Topics: Aged; Biotransformation; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Leucovorin; Methotrexate; Middle Aged	1987

Article

Year

Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells.

Biochemical pharmacology, 1987, Jul-15, Volume: 36, Issue:14

Topics: Breast Neoplasms; Cell Line; Folic Acid; Folic Acid Antagonists; Humans; Intracellular Fluid; Methotrexate; Neoplasm Proteins; Polyglutamic Acid; Tetrahydrofolate Dehydrogenase

1987

Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions.

Cancer drug delivery, 1987, Volume: 4, Issue:3

Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively. The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate. The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively. Urinary clearance of methotrexate was 3.46 +/- 1.4 1/h. In contrast, urinary excretion of 7-hydroxy-methotrexate was not linear. These results confirm the protein binding of metabolite to serum albumin and may suggest that distribution of 7-hydroxy-methotrexate is different from unchanged drug or that the metabolite can be eliminated by another route, such as bile.

Topics: Aged; Biotransformation; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Leucovorin; Methotrexate; Middle Aged

1987